SCHEMBL6818

SCHEMBL6818

O=[N+]([O-])Cc1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNJ1 P48048 1/20 0.43
KCNH2 Q12809 1/20 0.43
IDO1 P14902 3/20 0.42
LOXL2 Q9Y4K0 1/20 0.42
FBP1 P09467 2/20 0.42
HSPB1 P04792 1/20 0.41
SOS1 Q07889 1/20 0.40
TAAR1 Q96RJ0 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
ATM Q13315 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MAOA P21397 1/20 0.38
MAOB P27338 1/20 0.38
MDM2 Q00987 1/20 0.38
AGXT P21549 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9322428 0.87 LOXL2 (0.42) KCNJ1KCNH2IDO1LOXL2
SCHEMBL9810055 0.77 KCNJ1 (0.53) KCNJ1KCNH2IDO1LOXL2FBP1
SCHEMBL15167097 0.76 ALDH1A1 (0.40) IDO1LOXL2
SCHEMBL8854254 0.76 TAAR1 (0.39) IDO1LOXL2TAAR1SMN1; SMN2NPC1
SCHEMBL1087454 0.76 ALDH1A1 (0.50) IDO1LOXL2TDP1MEN1KMT2A
SCHEMBL3023794 0.76 IDO1 (0.38) IDO1FBP1ATMTDP1
SCHEMBL1281700 0.76 CYP1A2 (0.50) IDO1FBP1TAAR1LMNANPC1
SCHEMBL9610841 0.76 CA2 (0.45) IDO1TAAR1LMNATDP1MEN1
SCHEMBL5183837 0.76 ESR1 (0.46) IDO1FBP1TAAR1LMNANPC1
SCHEMBL11411468 0.76 LOXL2 (0.61) LOXL2TAAR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250109095-A1 METHOD FOR PREPARING OXIME DERIVATIVE SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2025-04-03 US disclosed
WO-2023101319-A1 METHOD FOR PREPARING OXIME DERIVATIVE 서울대학교산학협력단 2023-06-08 WO disclosed
CN-112457264-B Preparation method of hymexazol crude drug 湖北中牧安达药业有限公司 2023-03-31 CN disclosed
US-20150274661-A1 INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS HOFFMANN-LA ROCHE INC. (US) 2015-10-01 US disclosed
EP-2383268-B1 PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS ASTRAZENECA AB (SE) 2015-09-02 EP disclosed
EP-2909190-A1 INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS F. Hoffmann-La Roche AG (CH) 2015-08-26 EP disclosed
CN-104640853-A Indole-amide compounds as beta-amyloid inhibitors HOFFMANN LA ROCHE 2015-05-20 CN disclosed
US-8835465-B2 Pyrazolylaminopyridine derivatives useful as kinase inhibitors ASTRAZENECA AB (SE) 2014-09-16 US disclosed
WO-2014060386-A1 INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-04-24 WO disclosed
EP-2722329-A1 Indol-amide compounds as beta-amyloid inhbitors F. Hoffmann-La Roche AG (CH) 2014-04-23 EP disclosed
CN-101119996-A chemical compound ASTRAZENECA AB (SE) 2008-02-06 CN disclosed
EP-1853602-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2007-11-14 EP disclosed
EP-1846394-A1 PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS AstraZeneca AB (SE) 2007-10-24 EP disclosed
WO-2006087538-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2006-08-24 WO disclosed
EP-1691803-A1 N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS Warner-Lambert Company LLC (US) 2006-08-23 EP disclosed
WO-2006082392-A1 PYRAZOLYLAMINOPYRIDINE DERIVATIVES USEFUL AS KINASE INHIBITORS ASTRAZENECA AB (SE) 2006-08-10 WO disclosed
WO-2006059210-A2 FUSED BICYCLIC PYRROLS AS HMG-COA REDUCTASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2006-06-08 WO disclosed
US-20050154042-A1 N-alkyl pyrroles as HMG-CoA reductase inhibitors WARNER-LAMBERT COMPANY 2005-07-14 US disclosed
WO-2005056004-A1 N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2005-06-23 WO disclosed
US-4341898-A DEHYDROGENATION-ISOMERIZATION REACTION IN PRESENCE OF LEWIS ACID AIR PRODUCTS AND CHEMICALS, INC. (US) 1982-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154042-A1 N-alkyl pyrroles as HMG-CoA reductase inhibitors HMGCR, DHCR7, CYP11A1 KCNJ1 3996/4885KCNH2 3900/4885IDO1 2365/4885
US-20250109095-A1 METHOD FOR PREPARING OXIME DERIVATIVE NOS2, NOS1, NOS3 KCNJ1 4034/4885KCNH2 3291/4885IDO1 641/4885
US-20150274661-A1 INDOL-AMIDE COMPOUNDS AS BETA-AMYLOID INHBITORS APP, BACE1, IAPP KCNJ1 2279/4885KCNH2 1713/4885IDO1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.